Targeted Inhibition of Myeloperoxidase (MPO): A New Therapeutic Strategy for the Treatment of Multiple Myeloma

被引：1
|
作者：
Williams, Connor [1 ,2 ]
Noll, Jacqueline [1 ,2 ]
Harnas, Dylan [1 ,2 ]
Parkinson, Hayley [1 ,2 ]
Hewett, Duncan [1 ,2 ]
Wyllie, Kaitlin [3 ]
Cox, Thomas [3 ]
Zannettino, Andrew [1 ,2 ]
Vandyke, Kate [1 ,2 ]
Panagopoulos, Vasilios [1 ,2 ]
机构：
[1] Univ Adelaide, Sch Biomed, Fac Hlth & Med Sci, Myeloma Res Lab, Adelaide, SA, Australia
[2] South Australian Hlth & Med Res Inst, Precis Canc Med Theme, Adelaide, SA, Australia
[3] Garvan Inst, Matrix & Metastasis Lab, Sydney, NSW, Australia
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-179196
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Targeting Iron Homeostasis As a Therapeutic Strategy in Multiple Myeloma
    Ovejero-Merino, Sara
    Devin, Julie
    Caneque, Tatiana
    Alibert, Laura
    Requirand, Guilhem
    Robert, Nicolas
    Steer, Alizee
    Machura, Amelie
    Hirtz, Christophe
    Bruyer, Angelique
    Vincent, Laure
    Cartron, Guillaume
    Herbaux, Charles
    Rodriguez, Raphael
    Bret, Caroline
    Moreaux, Jerome
    BLOOD, 2022, 140 : 9980 - 9981
  • [42] Therapeutic strategy for multiple myeloma -recent progress-
    Chou, Takaaki
    ANNALS OF ONCOLOGY, 2016, 27
  • [43] Targeting of Adhesion Molecules as a Therapeutic Strategy in Multiple Myeloma
    Neri, Paola
    Bahlis, Nizar J.
    CURRENT CANCER DRUG TARGETS, 2012, 12 (07) : 776 - 796
  • [44] Proteasome inhibition and its therapeutic potential in multiple myeloma
    Chari, Ajai
    Mazumder, Amitabha
    Jagannath, Sundar
    BIOLOGICS-TARGETS & THERAPY, 2010, 4 : 273 - 287
  • [45] Proteomic analysis of targeted therapeutic agents in multiple myeloma (MM).
    Ghobrial, IM
    Eckel, JE
    Hoering, A
    Timm, M
    Leontovich, AA
    Fonseca, R
    Greipp, PR
    Witzig, TE
    BLOOD, 2004, 104 (11) : 160B - 160B
  • [46] Inhibition of the Heat Shock Transcription Factor 1 as a Potential New Therapeutic Strategy to Target Multiple Oncogenic Heat Shock Proteins in Multiple Myeloma.
    Heimberger, Tanja
    Andrulis, Mindaugas
    Fischbach, Stephanie
    Stuehmer, Thorsten
    Einsele, Hermann
    Bargou, Ralf C.
    Chatterjee, Manik
    BLOOD, 2009, 114 (22) : 1105 - 1106
  • [47] Inhibition of HIF1A signaling by a novel class of sulfonanilides for targeted treatment of multiple myeloma
    Hose, D.
    Seckinger, A.
    Goldschmidt, H.
    Meissner, T.
    Rebacz, B.
    Moreaux, J.
    Benes, V
    Neben, K.
    Hillengass, J.
    Bertsch, U.
    Jauch, A.
    Rossi, J. F.
    Moehler, T.
    Zimmermann, J.
    von Kalle, C.
    Lewis, J.
    Klein, B.
    Schultes, C.
    ONKOLOGIE, 2010, 33 : 280 - 281
  • [48] Inhibition of HIF1A Signaling by a Novel Class of Sulfonanilides for Targeted Treatment of Multiple Myeloma
    Hose, Dirk
    Seckinger, Anja
    Goldschmidt, Hartmut
    Meissner, Tobias
    Rebacz, Blanka
    Moreaux, Jerome
    Benes, Vladimir
    Neben, Kai
    Hillengass, Jens
    Bertsch, Uta
    Jauch, Anna
    Rossi, Jean Francois
    Moehler, Thomas
    Zimmermann, Juergen
    von Kalle, Christof
    Lewis, Joe
    Klein, Bernard
    Schultes, Christoph
    BLOOD, 2009, 114 (22) : 1115 - 1115
  • [49] Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma
    Heuck, Christoph
    Jethava, Yogesh
    Khan, Rashid Z.
    Miller, Scott
    Mitchell, Alan
    Johann, Donald
    Robbins, Kelly
    Van Laar, Ryan K.
    Ali, Siraj
    Miller, Vincent A.
    Bailey, Clyde
    Sawyer, Jeffery
    Zangari, Maurizio
    van Rhee, Frits
    Davies, Faith E.
    Morgan, Gareth J.
    Barlogie, Bart
    BLOOD, 2014, 124 (21)
  • [50] New treatment of multiple myeloma
    Hulin, C.
    REVUE DE MEDECINE INTERNE, 2007, 28 (10): : 682 - 688
12345